Integrating Newer ARVs into Current HIV Treatment Algorithms

2011_Therapeutic_Strategies_Webpage_Banner

2011_Therapeutic_Strategies_Launch_Program_Button.jpg

Click Launch Program Button to View Program Including a July 2011 Program UPDATE

Content Links:

Program Overview: 

Antiretroviral therapy (ART) for the treatment of the human immunodeficiency virus (HIV) has improved rapidly and steadily since the development of potent combination ART. With more than 20 approved antiretrovirals (ARVs) and 6 ARV classes, health care providers caring for HIV-positive patients have increasingly complex choices regarding ARV therapy for the management of treatment-naïve and treatment-experienced patients. While newer drugs may offer a new mechanism of action or improved potency, dosing convenience, or tolerability, keeping up with clinical trials on these newer ARVs and integrating their findings into existing treatment algorithms can be challenging.

This program consists of lively and thought-provoking open-forum, case-based presentations and discussions about how current HIV treatment algorithms may be impacted by newer ARVs. These CME programs will offer crucial new information on such issues as resistance, adverse effects, pharmacokinetics and adherence issues that will enable health care providers to incorporate new treatment options into existing treatment algorithms and discuss how these agents can be used to address the needs of a wide range of patient types and scenarios to provide individualized care that supports optimal patient outcome.

PLEASE NOTE: THIS ACTIVITY IS NO LONGER AVAILABLE FOR CME CREDIT  

Back to Top

Target Audience:

The target audience for this program is physicians, other health care providers and pharmacists who diagnose and manage patients with HIV/AIDS.

Back to Top 

Commercial Support Acknowledgement:

Supported by an unrestricted educational grant by Janssen Therapeutics.  

Back to Top

Learning Objectives: 

Upon completion of the program, participants should be able to:

  • Integrate newer ARVs into current treatment algorithms for the management of treatment-naïve patients, including clinical research that supports their use

  • Utilize resistance data to effectively use newer ARVs in treatment-experienced patients 

  • Utilize information regarding drug adverse events, drug pharmacokinetics and patient adherence to achieve ARV success 

  • Describe the importance of individualizing the care of each HIV-positive patient and how to incorporate that information into clinical practice

  • Discuss newer ARVs and how they may impact future care

PLEASE NOTE: THIS ACTIVITY IS NO LONGER AVAILABLE FOR CME CREDIT  

Release Date: June 15, 2011
Expiration Date: June 15, 2012

Estimated time to complete the Integrating Therapies Online Program: 2.25 hours

Media: Internet

Back to Top

Course Directors: 

JohnBartlett  John Bartlett, MD
Professor of Medicine,
Johns Hopkins University
Baltimore, Maryland
 CalvinCohen Calvin J. Cohen, MD, MS
Research Director,
CRI New England
Clinical Instructor,
Harvard Medical School
Boston, Massachusetts 
 Joseph_Eron_MD Joseph Eron, MD
Professor, 
University of North Carolina - Chapel Hill
School of Medicine
Chapel Hill, North Carolina
   

Back to Top

Faculty:

Richard A. Elion, MD
Associate Professor of Clinical Medicine,
George Washington University Medical Center
Clinical Research Director, Whitman-Walker Clinic
Washington, DC

Charles Hicks, MD
Professor,
Department of Medicine - Infectious Diseases
Duke University Medical Center
Durham, North Carolina

Judith Feinberg, MD
Professor of Medicine,
Associate Chair of Medicine for Faculty Development,
University of Cincinnati College of Medicine
Cincinnati, Ohio

Paul Sax, MD
Clinical Director,
Brigham and Women’s Division
of Infectious Diseases and HIV Program
Associate Professor of Medicine,
Harvard Medical School
Boston, Massachusetts

Andrew Zolopa, MD
Associate Professor of Medicine
Division of Infectious Diseases
Stanford University School of Medicine
Stanford, California

 

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Annenberg Center for Health Sciences at Eisenhower and ViralEd, Inc.. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Back to Top

Credit Designation Statement:

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Back to Top

Disclosure of Conflicts of Interest: 

The Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) assesses conflicts of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

John Bartlett, MD

  • Nothing to Disclose

Calvin Cohen, MD

  • Contracted Research: Gilead; Bristol-Myers Squibb; Merck & Co.; Tibotec; ViiV
  • Consulting Fees: Gilead; Abbott; Bristol-Myers Squibb; Merck & Co.; Tibotec
  • Fees for Non-CME/CE Services: Gilead; Bristol-Myers Squibb; Merck & Co.; Tibotec

Joseph Eron, MD

  • Contracted Research: Merck & Co.; GlaxoSmithKline; TaiMed
  • Consulting Fees: Avexa; Bristol-Myers Squibb; GlaxoSmithKline; Tibotec; Virco Laboratories; Pfizer; Tobira; Chimerix; Inhibix; Gilead; Vertex

Richard Elion, MD

  • Contracted Research: Gilead; Bristol-Myers Squibb; Merck & Co.; Tibotec; GlaxoSmithKline; Rapid
  • Consulting Fees: Gilead; Bristol-Myers Squibb; GlaxoSmithKline; Tibotec; Boehringer
  • Fees for Non-CME/CE Services: Gilead; Bristol-Myers Squibb; GlaxoSmithKline; Tibotec

Judith Feinberg, MD

  • Contracted Research: Bristol-Myers Squibb; Roche; Tibotec; Pfizer; GlaxoSmithKline
  • Consulting Fees: GlaxoSmithKline/ViiV; Merck & Co.; Tibotec
  • Fees for Non-CME/CE Services: Bristol-Myers Squibb; Tibotec; GlaxoSmithKline/Viiv; Merck & Co.

Andrew Zolopa, MD

  • Consulting Fees: Gilead Sciences; Tibotec; Bristol-Myers Squibb
  • Contracted Research: Gilead Sciences; Pfizer; Bristol-Myers Squibb; VIRxSyS

Paul Sax, MD

  • Consulting Fees: Abbott; Gilead; Bristol-Myers Squibb; GlaxoSmithKline; Merck & Co.; Tibotec; ViiV
  • Contracted Research: Gilead; Merck & Co.; Tibotec; ViiV

Charles Hicks, MD

  • Consulting Fees: Merck & Co.; Abbott; Tibotec; Gilead; GlaxoSmithKline; Bristol-Myers Squibb
  • Contracted Research: Merck & Co.; Argos; Tibotec; Gilead; GlaxoSmithKline; Bristol-Myers Squibb

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following planners and managers, Jan Hixon, RN, BSN, MA; Trace Hutchinson, PharmD; Julia Kimball, RN, BSN; Samantha Mattiucci, PharmD; Jan Schultz, RN, MSN, CCMEP; Patricia Staples, MSN, NP-C, CCRN, Gordon West, PhD, CCMEP; Brian Boyle, MD; Tracey Barrett, RN; Richard Gordon and Matthew Banks hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Back to Top

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), ViralEd, Inc. and Janssen Therapeutics do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, ViralEd, Inc. and Janssen Therapeutics. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Back to Top

Instructions for Participation and Credit

There are no fees for participating and receiving credit for this activity. During the period, June 15, 2011 through June 15, 2012, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and evaluation form.

To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on the Submit Post-test at the bottom of the page. Your post-test will automatically be graded.

If you successfully complete the post-test (score of 70% or higher). your certificate will be made available immediately. Click on View Certificate and print the certificate for your records. If you received a score of 69% or less, you will receive a message notifying you that you did not pass the post-test. You may retake the post-test until successful.

You may complete the Post-test on-line at www.cmeuniversity.com

  • Click on "Find Post-Test/Evaluation by Course" on the navigation menu
  • Search by project ID: 7864
  • Upon successfully completing the Post-test and Evaluation form, your certificate will be made available immediately.

Back to Top

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

We look forward to bringing the highest-quality CME directly to you.

PIM-4C-logo_sml   Annenberg_Centered_logo VE logo 300px


Prepare to print

Share this page:

Get link code to this page     


Back to Top